Published in Cancer Immunol Immunother on January 12, 2012
Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 3.07
Dendritic cells in the cancer microenvironment. J Cancer (2012) 1.40
T-cell exhaustion in the tumor microenvironment. Cell Death Dis (2015) 1.32
Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation. J Clin Invest (2013) 1.21
Shaping of NK cell responses by the tumor microenvironment. Cancer Microenviron (2012) 0.87
Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy. J Natl Cancer Inst (2015) 0.86
Plasmacytoid dendritic cells deficient in IFNα production promote the amplification of FOXP3(+) regulatory T cells and are associated with poor prognosis in breast cancer patients. Oncoimmunology (2013) 0.84
Splenectomy inhibits non-small cell lung cancer growth by modulating anti-tumor adaptive and innate immune response. Oncoimmunology (2015) 0.82
Immunosuppressive mechanisms of regulatory dendritic cells in cancer. Cancer Microenviron (2013) 0.81
Linking form to function: Biophysical aspects of artificial antigen presenting cell design. Biochim Biophys Acta (2014) 0.81
Origin and pharmacological modulation of tumor-associated regulatory dendritic cells. Int J Cancer (2014) 0.80
Molecular mimics of the tumour antigen MUC1. PLoS One (2012) 0.80
Twist and miR-34a are involved in the generation of tumor-educated myeloid-derived suppressor cells. Int J Mol Sci (2013) 0.79
Cervical (pre)neoplastic microenvironment promotes the emergence of tolerogenic dendritic cells via RANKL secretion. Oncoimmunology (2015) 0.78
Mechanisms and applications of interleukins in cancer immunotherapy. Int J Mol Sci (2015) 0.78
Effect of inhibition proliferation in human lung adenocarcinoma A549 cells by cytokine-induced killer cells. Thorac Cancer (2014) 0.78
Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy. ACS Nano (2015) 0.78
A pan-inhibitor of DASH family enzymes induces immune-mediated regression of murine sarcoma and is a potent adjuvant to dendritic cell vaccination and adoptive T-cell therapy. J Immunother (2013) 0.77
Spontaneous presence of FOXO3-specific T cells in cancer patients. Oncoimmunology (2014) 0.76
T-cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses. Mol Ther (2015) 0.76
Preimmunization of donor lymphocytes enhances antitumor immunity of autologous hematopoietic stem cell transplantation. Cancer Med (2013) 0.75
Effects of CIK on hypoxia inducible factor-1α and T-cell subsets on colon 26 cancer xenograft mice. Oncol Lett (2016) 0.75
Low molecular weight hyaluronan-pulsed human dendritic cells showed increased migration capacity and induced resistance to tumor chemoattraction. PLoS One (2014) 0.75
Enterobacteriaceae bacteremias among cancer patients: an observational cohort study. Int J Infect Dis (2013) 0.75
Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol (2005) 5.20
Retracted Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells. Cancer Res (2009) 2.00
Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages. J Leukoc Biol (2009) 1.51
MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res (2011) 1.39
Retracted High-avidity T cells are preferentially tolerized in the tumor microenvironment. Cancer Res (2012) 1.01
Novel regulation of CD80/CD86-induced phosphatidylinositol 3-kinase signaling by NOTCH1 protein in interleukin-6 and indoleamine 2,3-dioxygenase production by dendritic cells. J Biol Chem (2014) 0.91